Monthly Archives: July 2012

Specialty Biotech Companies Soaring in 2012 — Avanir Pharmaceuticals and CytRx Looking Strong

Posted on by

NEW YORK, NY--(Marketwire -07/17/12)- The Biotechnology Industry has been soaring in 2012 as companies -- both large and small -- have shown impressive growth. The SPDR S&P Biotech ETF (XBI) and the First Trust NYSE Arca Biotech Index ETF (FBT) year-to-date are up 37 percent and 35 percent, respectively, outperforming the broader market by a wide margin. The Paragon Report examines investing opportunities in the Biotechnology Industry and provides equity research on Avanir Pharmaceuticals, Inc. (AVNR) and CytRx Corporation (CYTR).

Access to the full company reports can be found at:

http://www.ParagonReport.com/AVNR

http://www.ParagonReport.com/CYTR

Despite having to negotiate a more challenging regulation process biotech companies have continued to show investors strong gains in 2012. The FDA Amendments Act of 2007 forced regulators to increase standards for approvals of new drugs, introducing mandatory risk evaluation and mitigation strategies. According to a Pharmaceuticals & Biotechnology report from IMAP, several pharmaceutical firms have altered their drug portfolios from primary care driven blockbusters towards specialties such as oncology, immunology and inflammation, where the medical need is "so high that prices are more easily accepted by the regulators."

Paragon Report releases regular market updates on the Biotechnology Industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at http://www.ParagonReport.com and get exclusive access to our numerous stock reports and industry newsletters.

Avanir Pharmaceuticals is a biopharmaceutical company focused on bringing innovative medicines to patients with central nervous system disorders of high unmet medical need. Avanir's NUEDEXTA is the first and only FDA-approved treatments for Pseudobulbar affect (PBA). PBA is characterized by involuntary, sudden, and frequent episodes of laughing and/or crying. Shares of the company have surged over 60 percent this year.

CytRx Corporation is a biopharmaceutical research and development company specializing in oncology. The CytRx oncology pipeline includes three programs in clinical development for cancer indications: INNO-206, tamibarotene and bafetinib. The company recently announced that the U.S. Patent and Trademark Office (USPTO) have issued a notice of allowance for a patent application with claims covering a pharmaceutical composition of tamibarotene in capsule form.

The Paragon Report has not been compensated by any of the above-mentioned publicly traded companies. Paragon Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at: http://www.paragonreport.com/disclaimer

Original post:
Specialty Biotech Companies Soaring in 2012 -- Avanir Pharmaceuticals and CytRx Looking Strong

Lexicon Pharmaceuticals and Rosetta Genomics Showing Impressive Growth in 2012

Posted on by

NEW YORK, NY--(Marketwire -07/18/12)- The Biotechnology Industry has been soaring in 2012 as companies -- both large and small -- have shown impressive growth. The SPDR S&P Biotech ETF (XBI) and the First Trust NYSE Arca Biotech Index ETF (FBT) year-to-date are up 37 percent and 35 percent, respectively, outperforming the broader market by a wide margin. The Paragon Report examines investing opportunities in the Biotechnology Industry and provides equity research on Lexicon Pharmaceuticals, Inc. (LXRX) and Rosetta Genomics Ltd. (ROSG).

Access to the full company reports can be found at: http://www.ParagonReport.com/LXRX http://www.ParagonReport.com/ROSG

Despite having to negotiate a more challenging regulation process biotech companies have continued to show investors strong gains in 2012. The FDA Amendments Act of 2007 forced regulators to increase standards for approvals of new drugs, introducing mandatory risk evaluation and mitigation strategies. According to a Pharmaceuticals & Biotechnology report from IMAP, several pharmaceutical firms have altered their drug portfolios from primary care driven blockbusters towards specialties such as oncology, immunology and inflammation, where the medical need is "so high that prices are more easily accepted by the regulators."

Paragon Report releases regular market updates on the Biotechnology Industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at http://www.ParagonReport.com and get exclusive access to our numerous stock reports and industry newsletters.

Lexicon is a biopharmaceutical company focused on discovering breakthrough treatments for human disease. Lexicon currently has five drug programs in mid-stage development for diabetes, carcinoid syndrome, irritable bowel syndrome, rheumatoid arthritis and glaucoma, all of which were discovered by Lexicon's research team. Shares of the company are up over 140 percent year-to-date.

Rosetta Genomics is a leading developer of microRNA-based diagnostic tests and therapeutic tools. MicroRNAs are a recently discovered group of short, non-coding genes which regulate the expression of other genes. MicroRNA-based diagnostics may offer physicians and patients an objective tool to accurately identify cancer, predict outcomes and help guide treatment.

The Paragon Report has not been compensated by any of the above-mentioned publicly traded companies. Paragon Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at: http://www.paragonreport.com/disclaimer

Excerpt from:
Lexicon Pharmaceuticals and Rosetta Genomics Showing Impressive Growth in 2012

Despite Facing Tougher Regulation Process Biotech Companies Showing Investors Impressive Gains in 2012

Posted on by

NEW YORK, NY--(Marketwire -07/18/12)- The Biotechnology Industry has been soaring in 2012 as companies -- both large and small -- have shown impressive growth. The SPDR S&P Biotech ETF (XBI) and the First Trust NYSE Arca Biotech Index ETF (FBT) year-to-date are up 37 percent and 35 percent, respectively, outperforming the broader market by a wide margin. The Paragon Report examines investing opportunities in the Biotechnology Industry and provides equity research on Alnylam Pharmaceuticals, Inc. (ALNY) and Nektar Therapeutics (NKTR).

Access to the full company reports can be found at: http://www.ParagonReport.com/ALNY http://www.ParagonReport.com/NKTR

Despite having to negotiate a more challenging regulation process biotech companies have continued to show investors strong gains in 2012. The FDA Amendments Act of 2007 forced regulators to increase standards for approvals of new drugs, introducing mandatory risk evaluation and mitigation strategies. According to a Pharmaceuticals & Biotechnology report from IMAP, several pharmaceutical firms have altered their drug portfolios from primary care driven blockbusters towards specialties such as oncology, immunology and inflammation, where the medical need is "so high that prices are more easily accepted by the regulators."

Paragon Report releases regular market updates on the Biotechnology Industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at http://www.ParagonReport.com and get exclusive access to our numerous stock reports and industry newsletters.

Alnylam is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company is leading the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases. Shares of the company surged over 50 percent Monday after reporting promising clinical results from its Phase I trial with ALN-TTR02.

Nektar Therapeutics is a biopharmaceutical company developing novel therapeutics based on its PEGylation and advanced polymer conjugation technology platforms. Nektar has a robust R&D pipeline of potentially high-value therapeutics in pain, oncology, and other therapeutic areas. The company recently announced the private placement of $125 million of Senior Secured Notes due in 2017.

The Paragon Report has not been compensated by any of the above-mentioned publicly traded companies. Paragon Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at: http://www.paragonreport.com/disclaimer

Continued here:
Despite Facing Tougher Regulation Process Biotech Companies Showing Investors Impressive Gains in 2012

International experts gather for AIBN event

Posted on by

The UQ Australian Institute for Bioengineering and Nanotechnology welcomes leading academics from around the world to its first International Conference on BioNano Innovation in July.

Among the conference's plenary speakers will be President of the Chinese Academy of Sciences, Professor Chunli Bai.

Other speakers include Lockheed Martin's Travis Earles; University of Toronto's Professor Peter Zandstra; CSIRO's Dr Ezio Rizzardo; and Harvard University's Dr Kenneth Chien.

The conference will run from July 18-20 at the Brisbane Convention and Exhibition Centre and cover topics such as vaccines, polymer nanostructures, nanomaterials, regenerative medicines and synthetic biology.

Conference convenor and AIBN Group Leader Professor Matt Trau said international experts in the field would gather in Brisbane for the event.

The conference aims to connect scientists, researchers and entrepreneurs in the rapidly-expanding areas of bioengineering and nanotechnology.

The intersection of biology with nanoscience and nanotechnology represents one of the most exciting wellsprings of scientific innovation, Prof Trau said.

Visit http://www.icbni.com.au

Media: Erik de Wit (0427 281 466, 3346 3962 or e.dewit@uq.edu.au)

Follow this link:
International experts gather for AIBN event

NASA | Before the Flare – Video

Posted on by

16-07-2012 16:12 The sun emitted a large flare on July 12, 2012, but earlier in the week it gave a demonstration of how gorgeous solar activity can be. This movie shows the sun from late July 8 to early July 10 shortly before it unleashed an X-class flare beginning at 12:11 PM EDT on July 12 as captured by the Solar Dynamics Observatory (SDO). The flare isn't shown here, but the movie shows how the sun is constantly, and complexly, active. The region responsible for the flare, known as Active Region 1520, and sitting in the lower left part of the sun, crackles with giant loops of magnetized solar material that can help scientists understand how magnetic energy in the region creates these giant explosions. On the right side of the sun, the shimmering loops offer us the last vision of Active Region 1515 -- which was also responsible for many solar flares -- as it disappears out of view along with the sun's rotation. The movie represents light in the 171 Angstrom wavelength, a wavelength of light that is particularly good at highlighting these magnetic loops. This video is public domain and can be downloaded at: Like our videos? Subscribe to NASA's Goddard Shorts HD podcast: Or find NASA Goddard Space Flight Center on facebook: Or find us on Twitter:

Visit link:

NASA | Before the Flare - Video

NASA expects Mars Odyssey orbiter to recover from malfunction

Posted on by

The 11-year-old orbiter tasked with monitoring Curiosity's landing has lost the use of one of its three reaction wheels, but NASA says it will be fine.

A veteran NASA spacecraft in orbit around Mars is slowly bouncing back from a malfunction suffered last month, but mission managers expect the orbiter to make a full recovery, agency officials said.

Subscribe Today to the Monitor

Click Here for your FREE 30 DAYS of The Christian Science Monitor Weekly Digital Edition

In early June, NASA's Mars Odyssey orbiter lost the use of one of its three reaction wheels, which help control the probe's attitude and orientation in space without needing to fire thrusters.

When the wheel jammed, Odyssey placed itself into a so-called safe mode, which points the spacecraft toward Earth (rather than its normal downward position facing Mars) to ensure better communications access. Mission controllers then instructed Odyssey to use a spare reaction wheel onboard as they assessed the situation.

On July 11, after performing a maneuver to adjust its orbit, Odyssey again placed itself into a precautionary safe mode. The spacecraft remained in this state for 21 hours before mission managers began recovering normal operations, according to NASA officials.

"It's out of safe mode and they're adding science observations and functions a day at a time, in the process of getting it back to full operations," said Guy Webster, a spokesman at NASA's Jet Propulsion Laboratory (JPL) in Pasadena, Calif. [Mars Odyssey: Pictures from Longest Mars Mission]

Mission controllers are expecting the 11-year-old orbiter to eventually resume its regular tasks.

"We are on a cautious path to resume Odyssey's science and relay operations soon," Gaylon McSmith, Odyssey project manager at JPL in Pasadena, Calif., said in a statement last week.

See the original post:

NASA expects Mars Odyssey orbiter to recover from malfunction

NASA says Mars Odyssey orbiter will likely recover from glitch (+video)

Posted on by

The 11-year-old orbiter tasked with monitoring Curiosity's landing has lost the use of one of its three reaction wheels, but NASA says it will be fine.

A veteran NASA spacecraft in orbit around Mars is slowly bouncing back from a malfunction suffered last month, but mission managers expect the orbiter to make a full recovery, agency officials said.

Subscribe Today to the Monitor

Click Here for your FREE 30 DAYS of The Christian Science Monitor Weekly Digital Edition

In early June, NASA's Mars Odyssey orbiter lost the use of one of its three reaction wheels, which help control the probe's attitude and orientation in space without needing to fire thrusters.

When the wheel jammed, Odyssey placed itself into a so-called safe mode, which points the spacecraft toward Earth (rather than its normal downward position facing Mars) to ensure better communications access. Mission controllers then instructed Odyssey to use a spare reaction wheel onboard as they assessed the situation.

On July 11, after performing a maneuver to adjust its orbit, Odyssey again placed itself into a precautionary safe mode. The spacecraft remained in this state for 21 hours before mission managers began recovering normal operations, according to NASA officials.

"It's out of safe mode and they're adding science observations and functions a day at a time, in the process of getting it back to full operations," said Guy Webster, a spokesman at NASA's Jet Propulsion Laboratory (JPL) in Pasadena, Calif. [Mars Odyssey: Pictures from Longest Mars Mission]

Mission controllers are expecting the 11-year-old orbiter to eventually resume its regular tasks.

"We are on a cautious path to resume Odyssey's science and relay operations soon," Gaylon McSmith, Odyssey project manager at JPL in Pasadena, Calif., said in a statement last week.

Originally posted here:

NASA says Mars Odyssey orbiter will likely recover from glitch (+video)

NASA hopes Mars rover landing will be 'grand and profound'

Posted on by

NASA's Curiosity Mars rover, which is scheduled to touch down on the Red Planet on August 6, is the most advanced robot ever sent to another world.

In the early morning hours of Aug. 6, NASA and space enthusiasts across the world will be able to monitor the Mars landing of the most advanced robot ever to be sent to another world.

Subscribe Today to the Monitor

Click Here for your FREE 30 DAYS of The Christian Science Monitor Weekly Digital Edition

Named Curiosity, the robot or rover has been heading toward Mars for nearly eight months. The landing is scheduled for 1:31 a.m. EDT.

Is it crazy? Not so much, said Doug McCuistion, the director of the Mars Exploration Program. Is it risky? Landing on Mars is always risky. Every landing is unique. Every landing is like a first.

At a news conference Monday, NASA scientists said they were looking for evidence that life existed on Mars billions of years ago. This evidence could include indicators of water, sources of energy or sources of carbon all of which are essential to sustain life.

Curiosity was launched into space last Nov. 26 from Cape Canaveral, Fla. The rover will go from 13,000 mph to zero in seven minutes, and will land in Gale Crater, which NASA scientists think held water billions of years ago.

In the middle of Gale is Mount Sharp, a mountain thats taller than any in the Lower 48 U.S. states, said John Grotzinger, a NASA scientist whos working on the mission. Curiosity will explore the crater and the mountain, looking for clues of life.

I see it as an extraordinary opportunity to get a bearing on our own existence on Earth, Grotzinger said. Ascending Mount Sharp, were going to go through the major eras in the history of Mars that give us the basis for comparison to our own planet.

Read this article:

NASA hopes Mars rover landing will be 'grand and profound'

Zyvex Marine launches LRV-17 Long Range Vessel as the first nano-composite manned boat

Posted on by

SEATTLE,COLUMBUS, Ohioand DUBAI, July 18, 2012 /PRNewswire/ -- Zyvex Marine, a division of Zyvex Technologies, the world's first molecular nanotechnology company, today announced the global launch of the LRV-17. The advanced Long Range Vessel is designed for fuel efficiency and rough sea stabilization with a sprint speed over 40 knots and a range of over 1,500 nautical miles, more than three times the range of comparatively sized vessels.

(Photo: http://photos.prnewswire.com/prnh/20120718/CG42070)

Global Maritime Security Solutions (GMSS), a leading maritime security company based in Dubai, will deploy the vessels for maritime security, including piracy protection, off the coast of Africa and surrounding areas.

The LRV-17 is built from Arovex, a carbon fiber nano-composite system (carbon fiber reinforced plastic enhanced with carbon nanotubes or CFRP-CNT) that reduces structural weight, allowing for more efficient fuel usage and increased range. This is the first time nano-composites have been used as the primary material for a manned vessel.

The LRV-17 is modeled after the Piranha Unmanned Surface Vessel, which debuted in 2010. The Piranha received global attention and established Zyvex as a pioneer of nano-composite marine manufacturing. The vessel now joins several technology applications using Arovex.

"As the first molecular nanotechnology engineering company in the marine industry, we are proud to launch a manned vessel platform after successfully proving the unmanned platform and then introducing the industry's lightest and most durable doors, hatches, and other marine closures. These applications of nano-composites are advancing commercial and defense partners' capabilities when it comes to safety and efficiency," said Byron Nutley, Vice President of Zyvex Technologies and General Manager of Zyvex Marine.

The 17-meter (57-foot) vessel's deep-V hull is designed for fuel efficiency and uses an active gyroscope stabilizer for improved sea handling and decreased human fatigue factors. It is fully deployable with only two operators and can be equipped with an additional four shock-mitigating seats for support personnel, allowing six crew to remain at sea for over five days. Zyvex Marine performed primary design and engineering, with secondary engineering, installation, and test analysis being performed by partners Pacific Coast Marine, S3 Maritime, Eltech Electric, Seakeeper, and Donald L. Blount and Associates.

GMSS plans to launch a Merchant Vessel Convoy Escort Program by deploying security teams to operatetwo LRV-17s to protect ships en route. According to the Council on Foreign Relations, there were 439 worldwide piracy attacks in 2011. One report estimated the piracy impact on the global economy to be $7 billion for 2011, the most detailed estimate to date. (1)

"The new LRV-17 boats are game changers in maritime security missions because they are the only vessels capable of long range escort and high speeds to deal with multiple pirate threats. They need only small security teams to effectively operate," said Rhynhardt Berrange, Managing Director of GMSS. "These attributes create a cost-effective platform to ensure maritime security. The visible presence of the new vessels is expected to deter and help prevent piracy attempts and attacks."

(1) One Earth Future's Ocean Beyond Piracy Initiative - http://www.cfr.org/france/combating-maritime-piracy/p18376

See more here:

Zyvex Marine launches LRV-17 Long Range Vessel as the first nano-composite manned boat

New Report Sports Medicine Devices Market (2012-2017) by MarketsandMarkets

Posted on by

Sports medicine devices market research report provides comprehensive analysis on global market of sports medicine by products/devices, applications and technology.(PRWEB) July 18, 2012 Sports medicine is a very dynamic field of medicine which has made a mark in the healthcare sector only in the last decade. The field has witnessed a spurt in technology and has grown with the rise in the medical ...

Originally posted here:

New Report Sports Medicine Devices Market (2012-2017) by MarketsandMarkets

Penn Medicine Hospitals Recognized for Outstanding Performance by

Posted on by

PHILADELPHIA The Hospital of the University of Pennsylvania (HUP) (www.pennmedicine.org) has once again been ranked among the top hospitals in the nation by U.S. News & World Report. The publication's annual ranking of hospitals in America lists HUP as one of only 17 hospitals in the nation to be recognized as an "Honor Roll" hospital for its exceptional performance, based on outstanding quality, expertise, technology, and experience. According to the editors, the Honor Roll distinction "signals both rare breadth and rare depth of medical excellence." HUP is the only hospital in the Philadelphia region to make the 2012-2013 Honor Roll.

In the publication's rating of regional hospitals, all three Penn Medicine hospitals were among the top 10 hospitals in Philadelphia. HUP again topped the list at #1, while Penn Presbyterian Medical Center and Pennsylvania Hospital ranked 3rd and 5th respectively. All three Penn Medicine hospitals also ranked among the top 10 hospitals in Pennsylvania.

###

Penn Medicine is one of the world's leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System, which together form a $4.3 billion enterprise.

The Perelman School of Medicine is currently ranked #2 in U.S. News & World Report's survey of research-oriented medical schools. The School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $479.3 million awarded in the 2011 fiscal year.

The University of Pennsylvania Health System's patient care facilities include: The Hospital of the University of Pennsylvania -- recognized as one of the nation's top 10 hospitals by U.S. News & World Report; Penn Presbyterian Medical Center; and Pennsylvania Hospital the nation's first hospital, founded in 1751. Penn Medicine also includes additional patient care facilities and services throughout the Philadelphia region.

Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2011, Penn Medicine provided $854 million to benefit our community.

Read more:

Penn Medicine Hospitals Recognized for Outstanding Performance by

Southern California University of Health Sciences to Welcome Beijing University of Chinese Medicine

Posted on by

WHITTIER, Calif.--(BUSINESS WIRE)--

Southern California University of Health Sciences (SCU), one of the United States most established universities for the study of integrative and complementary medicine, is proud to welcome a special delegation of Traditional Chinese Medicine administrators from the Peoples Republic of China on Thursday, July 19, 2012.

Comprised of officials and key personnel from the State Administration of Traditional Chinese Medicine and three other Chinese TCM schools, the delegation will arrive to strengthen and expand the current educational collaborative agreements and scholarly exchange programs with SCU.

They will be received by SCU President Dr. John Scaringe to discuss the current state of TCM education in the United States, and the future direction. Their meeting will include an exchange of gifts among team members, a tour of the 38-acre SCU campus, as well as the sharing of insights and opinions on topics relating to Traditional Chinese Medicine and the international community.

We are very honored with this State visit from the Official Chinese delegation, stated Dr. Scaringe. We look forward to forging stronger ties and developing additional opportunities for scholarly exchange.

SCU is recognized in China as a leading institution for Traditional Chinese Medicine in the United States. For more than 10 years, SCUs College of Acupuncture and Oriental Medicine (CAOM has been the only regionally accredited Acupuncture and Oriental Medicine (AOM) program by the Western Association of Schools and Colleges (WASC) in California.

A testament to the quality of the AOM program at SCU is the fact that the Chinese government, through the Beijing University of Chinese Medicine, has awarded PhD scholarships for TCM to graduates from the CAOM at SCU. In 2011, the Chinese government awarded two PhD scholarships through the Beijing University of Chinese Medicine for two recent SCU AOM graduates.

About Southern California University of Health Sciences:

Since 1911, SCU has prepared thousands of men and women for fulfilling careers in some of the fastest-growing areas of the healthcare industry. Comprised chiefly of the Los Angeles College of Chiropractic and the College of Acupuncture and Oriental Medicine, our comprehensive campus in Whittier, California includes a University Health Center and a School of Professional Studies to give our students a well-rounded and hands-on educational experience.

See the original post:

Southern California University of Health Sciences to Welcome Beijing University of Chinese Medicine

Research and Markets: Sports Medicine Implants Market – Global Pipeline Analysis, Competitive Landscape and Market …

Posted on by

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/j6jdjs/sports_medicine_im) has announced the addition of GlobalData's new report "Sports Medicine Implants Market - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2018" to their offering.

Sports Medicine Implants Market Sprints Ahead as Injuries Become More Common

The growing number of people injuring themselves during sport is driving the sports medicine implants market, states a new report by healthcare experts GlobalData.

According to the research*, an increase in injury rates in combination with an aging population and more technologically advanced implant options will see the global sports medicine implant market grow from a 2011 figure of $1 billion, to reach $1.6 billion by 2018, at a Compound Annual Growth Rate (CAGR) of 6.7%.

The US has the largest market for these implants, accounting for 49% of the global market last year. The 2011 value stood at $517.8m, which GlobalData expects will increase at a CAGR of 6.8% by 2018 to reach $820m.

There was a 27% increase in football-related injuries among children and adolescents aged between six and 17 years during 1990-2007, with an estimated 5,252,721 being treated in US emergency departments. Soft tissue damage accounted for approximately 24% of these injuries - an ailment that often requires the use of sport medicine implants.

Advances in implant technology are also set to play a role in boosting the sports medicine implants market. There is a growing preference for implants constructed from biocomposite materials, due to their greater efficacy and safety when compared to traditional metal varieties.

Advantages of newer implants also enable easier post-operative imaging, revision surgery, and the enabling of bone formation within the screw. These implants are, however, more expensive than their metal counterparts, and most major manufacturers have launched biocomposite models in order to benefit financially from the surging adoption rates.

Companies Mentioned

See the original post here:

Research and Markets: Sports Medicine Implants Market - Global Pipeline Analysis, Competitive Landscape and Market ...

Mevion Medical Systems Delivers the MEVION S250 Superconducting Synchrocyclotron to Robert Wood Johnson University …

Posted on by

LITTLETON, Mass.--(BUSINESS WIRE)--

Mevion Medical Systems announced today that it has delivered the superconducting synchrocyclotron for the MEVION S250 Proton Therapy System currently under installation at Robert Wood Johnson University Hospital in New Brunswick, NJ, the flagship cancer hospital of The Cancer Institute of New Jersey and the principal teaching hospital of UMDNJ-Robert Wood Johnson Medical School. This is the second MEVION S250 proton therapy system delivered in the past 6 months, both installed at NCI-designated Comprehensive Cancer Centers.

Powered by a TriNiobium Core, the MEVION S250 is a modern and first-of-its-kind proton therapy system that provides the same precise, non-invasive treatment capabilities and advantages of complex, large, and costly proton therapy systems but with a significantly reduced footprint, improved reliability, more advanced clinical systems, and lower implementation and operational costs. Robert Wood Johnson University Hospital has a proud history of clinical innovation and a commitment to provide the highest quality and value of services to its patients and community, says Stephen K. Jones, FACHE, President and Chief Executive Officer, Robert Wood Johnson University Hospital and Robert Wood Johnson Health System. We are excited to be the first in the northeast to receive this revolutionary technology and add this innovative proton therapy service to our comprehensive list of cancer services.

In addition to offering proton beam therapy and Gamma Knife Perfexion for the treatment of brain tumors, The Cancer Hospital at RWJUH is the flagship hospital of The Cancer Institute of New Jersey (CINJ), the states only National Cancer Institute-designated Comprehensive Cancer Center and the hospitals cancer program has been accredited by the American College of Surgeons Commission on Cancer. The partnership between RWJUH, UMDNJ-RWJMS and CINJ offers patients a unique opportunity to benefit from clinical research performed at CINJ while receiving expert care from faculty and community physicians in a state-of-the-art environment at RWJUH. RWJUHs cancer program was recently ranked among the top 50 programs in the United States by U.S.News & World Report as part of its 2012 ranking of Americas Best Hospitals.

Manufactured in Massachusetts, it took only one day for the MEVION S250 accelerator to travel to New Jersey and only a few hours to be brought inside the proton center. The proton therapy modernization and size reduction that we deliver today has redefined the economics and accessibility of proton therapy, says Joseph K. Jachinowski, Chief Executive Officer of Mevion Medical Systems. We are delighted to be entering this final installation phase of the MEVION S250 proton therapy system at another leading cancer hospital.

The MEVION S250 has recently received United States Food and Drug Administration 510(k) clearance and CE Certification enabling Mevion customers to treat patients. With four centers under installation or construction and more than a dozen under planning, Mevion has quickly established itself as a leading proton therapy supplier worldwide.

ABOUT MEVION MEDICAL SYSTEMS Mevion Medical Systems, Inc. is a radiation therapy company dedicated to advancing the treatment of cancer. As the pioneering developer of modern proton therapy systems, Mevion provides innovative, safe, and effective solutions by transforming advances in medical technology and science into practical clinical reality.

Mevions flagship product, the MEVION S250 Proton Therapy System, is designed to preserve all of the treatment benefits of traditional proton therapy systems while removing the obstacles of size, cost, and complexity. Realizing this vision, Mevion has forever changed the economics and accessibility of proton therapy worldwide.

Founded in 2004, Mevion is a privately held company headquartered in the Boston metropolitan area with international offices in the United Kingdom and Japan.

Visit us at: http://www.mevion.com

The rest is here:

Mevion Medical Systems Delivers the MEVION S250 Superconducting Synchrocyclotron to Robert Wood Johnson University ...

Oregon school for osteopathy has strong start

Posted on by

Three days a week, Dr. Robin Richardson practices urgent care for Providence Health, while the other two days he spends on a passion far less profitable: primary care for more than 2,000 people.

I have one family where I take care of four generations. Its just a good feeling, he said of his family practice in Southeast Portland.

Richardson is one of dozens of Oregon osteopathic physicians who rallied to help a new medical school get its footing in Lebanon. Called the College of Osteopathic Medicine of the Pacific-Northwest, the new school has completed its first year.

Its the states second mainstream medical school after Oregon Health & Science University, and could help fill a wave of demand for primary care physicians caused by federal health reform.

The college has helped revitalize the former lumber town of 15,000 by leasing a 54,000-square-foot brick building from Samaritan Health Services, just across from Lebanon Community Hospital. COMPs main branch, in Pomona, Calif., has sent graduates for residencies at the hospital for years.

Now Richardson and other local doctors give occasional lectures, oversee students during their residencies and interview prospective new students once a month.

The school has energized Oregons osteopathic physicians who lacked a place to connect after Portlands Eastmoreland Hospital, with its focus on osteopathic medicine, shut down nearly a decade ago, says John Pham, an osteopathic physician from Portland who serves on the colleges faculty. Its like any small culture. We all help each other and we want to see each other succeed. I think its different from the MDs there are so many of them.

Osteopathic medicine started as a holistic offshoot of traditional medicine, but gained acceptance by the U.S. medical establishment long ago. Yet doctors of osteopathy, or DOs, remain a minority about 625 in Oregon versus 10,000 MDs.

The college hopes to start changing that and, along the way, provide new doctors where theyre most needed. My goal is 80 percent of our grads going into primary care, Richardson said.

About 107 students, 56 of them male, signed up for the schools inaugural class. Only two students took a leave of absence and didnt finish the year. It was due to personal reasons, not performance, says Paula Crone, the schools associate executive dean. Theyve already selected the class that starts in August.

More here:

Oregon school for osteopathy has strong start

Richard Hyatt: A medical school comes to Columbus

Posted on by

Columbus Regional and St. Francis have wasted a lot of time fussing when they should have been caring for the sick, but this week the dueling hospitals embarked on a project that has inspired them to put down their scalpels.

The presence of a medical school in Columbus is something the two facilities can celebrate, and over the past five months, they've joined forces to prepare for the arrival of 14 third-year students from the Mercer University School of Medicine.

For years the hospitals have engaged in turf wars that never made sense to anyone outside the upper echelons of the medical community. Proponents of the medical school somehow crossed bridges that no one thought were there.

Dr. David Mathis, an assistant dean and 1986 Mercer Medical School graduate, said leaders of the hospitals have openly acknowledged that they haven't always worked together and that the alliances formed by this project are a positive step.

Though progress has been made, students are spending this week filling out mounds of repetitive paperwork required to do business at the two facilities. "If there are duplications, we've advised the students to be patient," Mathis said.

Since 1982, Mercer has prepared physicians to practice medicine in underserved areas of Georgia on their traditional campus in Macon. Four years ago, an auxiliary campus opened in Savannah and plans to expand into Columbus were announced in February.

For now, the school is housed at the Bradley Center. A student coordinator will be hired and distant-learning facilities are being installed. Mathis will be based in Macon but will spend a lot of time here.

"The hospitals and the doctors in Columbus have been so welcoming," Mathis said. "Each hospital appointed a lead physician, and they've been extremely helpful."

Dr. John Bucholtz, a family-practice physician, represents the Medical Center. Dr. Luther Wolff III, an orthopedic surgeon, is the St. Francis appointee. A team of local doctors will serve as mentors.

Mercer's mission is unique. It accepts only students from Georgia and encourages graduates to practice in the state. After 30 years, two out of every three graduates are practicing in Georgia. This is crucial around Columbus, where 25 percent of the physicians are age 55 or older.

Read the original here:

Richard Hyatt: A medical school comes to Columbus

UMass Medical School to manage health care at federal prison in North Carolina

Posted on by

By Chris Reidy, Globe Staff

The Federal Bureau of Prisons has awarded the University of Massachusetts Medical School a contract to manage comprehensive medical services to about 4,900 inmates at the Federal Medical Center located in Butner, N.C., UMass Medical School said.

The agreement, valued at $24.7 million for the first year, represents its largest federal correctional health contract to date, the Worcester-based school said.

The contract also has options for four additional years that could increase the overall award to more than $136 million through 2016, the school said

The school considers itself a leader in correctional health; it has also provided comprehensive health services for the past 12 years at the Federal Bureau of Prisons medical facility in Devens. The school said it also has a long track record of providing care at 17 state-run prisons in Massachusetts, serving the health needs of 11,500 inmates.

Originally posted here:

UMass Medical School to manage health care at federal prison in North Carolina

Wolf-dog Liberty settles into new wolf sanctuary home

Posted on by

LITITZ, Pa. - The wolf-dog met the media Tuesday, panting but content.

The animal formerly known as Levi was introduced to the public with a new name - Liberty - to reflect his connection to Philadelphia, where he was loose in Pennypack Park from March until his capture July 3.

That's his third name in five months; when he was only a ghostly, lurking presence in the park, before anyone knew he was Levi, Liberty was actually called Penny. Life has been changing fast ever since for the young animal, believed to be around 10 months old.

Off dog food these days, Liberty is now eating raw meat, as befits a gray wolf-Malamute hybrid. The belief is, in fact, that he is significantly more wolf than dog - chromosomally connected to legendary moon-howling pack animals who live life on their own terms.

Beyond domesticity, Liberty is too cool for obedience school, and too dangerous to be outfitted with bandannas and expected to catch and return Frisbees like some slobbering Lab in the park.

Instead, he currently lives with his dignity intact at the 22-acre Speedwell Forge Wolf Sanctuary, a private, nonprofit licensed by the Pennsylvania Game Commission.

Liberty was taken there after being trapped by agents of the Commission and the U.S. Department of Agriculture's APHIS Wildlife Services division.

The animal's owner, Kasey Lyons, who didn't have a permit for Liberty - then Levi - was visiting from Florida with the animal last March. Liberty had been a gift from Lyons to his former fiancee.

But love failed, and after the two broke up, the fiancee no longer wanted the wolf-dog. Liberty, collateral damage in the failed romance, suddenly found himself wandering Pennypack Park. It's not clear whether he escaped or was set loose, although unwanted hybrids are typically abandoned, wolf experts say.

On the hoof and all alone, Liberty survived on pet food he'd cleverly pilfered from yards, as well as on pizza and McDonald's burgers that neighbors said they threw him.

View original post here:

Wolf-dog Liberty settles into new wolf sanctuary home